Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Scott Guenthner
Observed names:
S. Guenthner,
Scott T Guenthner,
Scott T. Guenthner,
Scott Thomas Guenthner
Institution:
Indiana Clinical Trials Center
Observed institutions:
University of Southern California,
University of British Columbia,
Henry Ford Health,
Eastern Virginia Medical School,
Yale University,
Probity Medical Research,
Indiana Clinical Trials Center,
Indiana University School of Medicine,
Icahn School of Medicine at Mount Sinai
show all 9
ORCID:
0000-0002-6660-2245
Observed ORCID:
0000-0002-6660-2245
OpenAlex ID:
A5025746305
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
2021
·
Mark G. Lebwohl
, Linda Stein Gold
, et al.
·
New England Journal of Medicine
·
246
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
2023
·
Eric L. Simpson
, Melinda Gooderham
, et al.
·
JAMA Dermatology
·
182
PDF
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
2019
·
A. Blauvelt
, K. Papp
, et al.
·
British Journal of Dermatology
·
182
PDF
Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation
1999
·
Scott T. Guenthner
, Robert M. Hurwitz
, et al.
·
Journal of the American Academy of Dermatology
·
93
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
2018
·
Angela Moore
, Lawrence J Green
, et al.
·
PubMed
·
80
Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
2015
·
Caroline P. Schaefer
, Joseph C. Cappelleri
, et al.
·
Journal of the American Academy of Dermatology
·
65
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
2024
·
Andrew Blauvelt
, Zoe D. Draelos
, et al.
·
Journal of the American Academy of Dermatology
·
55
PDF
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial
2023
·
Matthew J. Zirwas
, Zoe D. Draelos
, et al.
·
JAMA Dermatology
·
51
PDF
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
2023
·
Melinda Gooderham
, Leon Kircik
, et al.
·
Journal of Drugs in Dermatology
·
51
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
2019
·
Mark G. Lebwohl
, Andrew Blauvelt
, et al.
·
American Journal of Clinical Dermatology
·
46
PDF
Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry
2022
·
Aleksandar Sekulic
, Simon Yoo
, et al.
·
PLoS ONE
·
21
PDF
The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis
2022
·
Joyce M.C. Teng
, Christopher G. Bunick
, et al.
·
Journal of the American Academy of Dermatology
·
17
PDF
A skin cancer education initiative at a professional baseball game and results of a skin cancer survey
2003
·
Emily Ann Jungers
, Scott Thomas Guenthner
, et al.
·
International Journal of Dermatology
·
17
Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials
2025
·
Neal Bhatia
, James Del Rosso
, et al.
·
JAMA Dermatology
·
16
Quantifying skin photodamage with spatial frequency domain imaging: statistical results
2019
·
Jeffrey B. Travers
, Chien Poon
, et al.
·
Biomedical Optics Express
·
13
Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials
2020
·
Mark Lebwohl
, Linda Stein Gold
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
11
PDF
Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
2017
·
David Pariser
, Michael Bukhalo
, et al.
·
PubMed
·
8
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis
2023
·
Dedee F Murrell
, Joyce M C Teng
, et al.
·
Clinical and Experimental Dermatology
·
7
PDF
COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug–Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts
2021
·
Scott Guenthner
, Wendy McFalda
, et al.
·
Dermatology and Therapy
·
7
PDF
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study
2020
·
Melinda J. Gooderham
, Leon H. Kircik
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
6
PDF
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study
2023
·
Kalyani Marathe
, Joyce M. C. Teng
, et al.
·
Dermatology and Therapy
·
5
PDF
Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials
2026
·
Linda Stein Gold
, April W Armstrong
, et al.
·
British Journal of Dermatology
·
4
31865 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis
2022
·
Mark Lebwohl
, Melinda J
, et al.
·
Journal of the American Academy of Dermatology
·
2
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts
2021
·
Scott Guenthner
, Wendy McFalda
, et al.
·
American Journal of Clinical Dermatology
·
2
PDF
Inter- and Intra-Physician Variation in Quantifying Actinic Keratosis Skin Photodamage
2020
·
Benjamin Schmeusser
, Christina Borchers
, et al.
·
Journal of Clinical and Investigative Dermatology
·
2
PDF
Show more works
View as search
Works count:
43
Citation count:
1,200
H-index:
14
I10-index:
16
Year
Topic
Type